TY - JOUR
T1 - α2-adrenergic stimulation and vasopressin in congestive heart failure
AU - Goldsmith, Steven R.
AU - Dodge-Brown, Donna L.
AU - Katz, Adriana
PY - 1989/9
Y1 - 1989/9
N2 - Patients with chronic heart failure (CHF) have increased plasma levels of the antidiuretic hormone arginine vasopressin (AVP). The stimulus for increased AVP secretion is unknown, but appears to involve a non-osmotic drive which alters normal osmoregulatory mechanisms. Centrally acting α2-adrenergic agonists suppress AVP secretion in experimental animals. To examine the hypothesis that such effects might be apparent on the chronically elevated AVP levels in patients with CHF, we measured AVP, heart rate (HR), mean arterial pressure (MAP), and plasma norepinephrine (NE) after 4 mg oral guanabenz in nine patients with this disease. Plasma NE decreased from 513 ± 131 to a minimum of 371 ± 117 pg/ml (p < 0.02) 5 h postdrug. HR decreased from 80 ± 9.3 to 74 ± 10 beats/min (p < 0.05) and MAP decreased from 88 ± 8.5 to 83 ± 10 mm Hg (p < 0.05). Plasma AVP, however, did not change from baseline levels of 5.6 ± 1.6 pg/ml. Serum osmolality was also constant. These data do not support a possible role for acute increases of α2-adrenergic activity in suppressing the increased plasma AVP levels of CHF, at least under basal conditions at constant osmolality.
AB - Patients with chronic heart failure (CHF) have increased plasma levels of the antidiuretic hormone arginine vasopressin (AVP). The stimulus for increased AVP secretion is unknown, but appears to involve a non-osmotic drive which alters normal osmoregulatory mechanisms. Centrally acting α2-adrenergic agonists suppress AVP secretion in experimental animals. To examine the hypothesis that such effects might be apparent on the chronically elevated AVP levels in patients with CHF, we measured AVP, heart rate (HR), mean arterial pressure (MAP), and plasma norepinephrine (NE) after 4 mg oral guanabenz in nine patients with this disease. Plasma NE decreased from 513 ± 131 to a minimum of 371 ± 117 pg/ml (p < 0.02) 5 h postdrug. HR decreased from 80 ± 9.3 to 74 ± 10 beats/min (p < 0.05) and MAP decreased from 88 ± 8.5 to 83 ± 10 mm Hg (p < 0.05). Plasma AVP, however, did not change from baseline levels of 5.6 ± 1.6 pg/ml. Serum osmolality was also constant. These data do not support a possible role for acute increases of α2-adrenergic activity in suppressing the increased plasma AVP levels of CHF, at least under basal conditions at constant osmolality.
KW - Guanabenz
KW - Vasopressin
KW - α Adrenoceptors
UR - http://www.scopus.com/inward/record.url?scp=0024397279&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024397279&partnerID=8YFLogxK
U2 - 10.1097/00005344-198909000-00011
DO - 10.1097/00005344-198909000-00011
M3 - Article
C2 - 2476622
AN - SCOPUS:0024397279
SN - 0160-2446
VL - 14
SP - 425
EP - 429
JO - Journal of Cardiovascular Pharmacology
JF - Journal of Cardiovascular Pharmacology
IS - 3
ER -